- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 282641, 7 pages
Different Levels in Orexin Concentrations and Risk Factors Associated with Higher Orexin Levels: Comparison between Detoxified Opiate and Methamphetamine Addicts in 5 Chinese Cities
1School of Public Health, Peking University, Beijing 100191, China
2National Institute on Drug Dependence, Peking University, 38 Xueyuan Road Haidian District, Beijing 100191, China
3Institute of Basic Research in Clinical Medicine, Academy of Chinese Medical Sciences, Beijing 100700, China
Received 2 April 2013; Accepted 1 August 2013
Academic Editor: Alfredo Conti
Copyright © 2013 Haoran Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. K. Pasumarthi and J. Fadel, “Stimulation of lateral hypothalamic glutamate and acetylcholine efflux by nicotine: implications for mechanisms of nicotine-induced activation of orexin neurons,” Journal of Neurochemistry, vol. 113, no. 4, pp. 1023–1035, 2010.
- J. P. Wisor, S. Nishino, I. Sora, G. H. Uhl, E. Mignot, and D. M. Edgar, “Dopaminergic role in stimulant-induced wakefulness,” Journal of Neuroscience, vol. 21, no. 5, pp. 1787–1794, 2001.
- S. Taheri and S. Hafizi, “The orexins/hypocretins: hypothalamic peptides linked to sleep and appetite,” Psychological Medicine, vol. 32, no. 6, pp. 955–958, 2002.
- Y. Yoshida, N. Fujiki, R. A. Maki, D. Schwarz, and S. Nishino, “Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats,” Neuroscience Letters, vol. 346, no. 3, pp. 182–186, 2003.
- O. Selbach, K. S. Eriksson, and H. L. Haas, “Drugs to interfere with orexins (Hypocretins),” Drug News and Perspectives, vol. 16, no. 10, pp. 669–681, 2003.
- M. Ishibashi, S. Takano, H. Yanagida et al., “Effects of orexins/hypocretins on neuronal activity in the paraventricular nucleus of the thalamus in rats in vitro,” Peptides, vol. 26, no. 3, pp. 471–481, 2005.
- R. Tao, Z. Ma, J. T. McKenna et al., “Differential effect of orexins (hypocretins) on serotonin release in the dorsal and median raphe nuclei of freely behaving rats,” Neuroscience, vol. 141, no. 3, pp. 1101–1105, 2006.
- M. E. Carter, J. S. Borg, and L. de Lecea, “The brain hypocretins and their receptors: mediators of allostatic arousal,” Current Opinion in Pharmacology, vol. 9, no. 1, pp. 39–45, 2009.
- K. S. Eriksson, O. A. Sergeeva, H. L. Haas, and O. Selbach, “Orexins/hypocretins and aminergic systems,” Acta Physiologica, vol. 198, no. 3, pp. 263–275, 2010.
- P. J. Kenny, “Tobacco dependence, the insular cortex and the hypocretin connection,” Pharmacology Biochemistry and Behavior, vol. 97, no. 4, pp. 700–707, 2011.
- Y. Li, H. Wang, K. Qi et al., “Orexins in the midline thalamus are involved in the expression of conditioned place aversion to morphine withdrawal,” Physiology and Behavior, vol. 102, no. 1, pp. 42–50, 2011.
- C. Von der Goltz, A. Koopmann, C. Dinter et al., “Involvement of orexin in the regulation of stress, depression and reward in alcohol dependence,” Hormones and Behavior, vol. 60, no. 5, pp. 644–650, 2011.
- L. De Lecea and J. G. Sutcliffe, “The hypocretins/orexins: novel hypothalamic neuropeptides involved in different physiologicaI systems,” Cellular and Molecular Life Sciences, vol. 56, no. 5-6, pp. 473–480, 1999.
- S. Taheri and S. Bloom, “Orexins/hypocretins: waking up the scientific world,” Clinical Endocrinology, vol. 54, no. 4, pp. 421–429, 2001.
- S.-X. Li, L.-J. Liu, W.-G. Jiang et al., “Circadian alteration in neurobiology during protracted opiate withdrawal in rats,” Journal of Neurochemistry, vol. 115, no. 2, pp. 353–362, 2010.
- S. Taheri, J. M. Zeitzer, and E. Mignot, “The role of hypocretins (Orexins) in sleep regulation and narcolepsy,” Annual Review of Neuroscience, vol. 25, pp. 283–313, 2002.
- M. López, M. Tena-Sempere, and C. Diéguez, “Cross-talk between orexins (hypocretins) and the neuroendocrine axes (hypothalamic-pituitary axes),” Frontiers in Neuroendocrinology, vol. 31, no. 2, pp. 113–127, 2010.
- J. A. Bonini, K. A. Jones, N. Adham et al., “Identification and characterization of two G protein-coupled receptors for neuropeptide FF,” Journal of Biological Chemistry, vol. 275, no. 50, pp. 39324–39331, 2000.
- G.-C. Zhang, L.-M. Mao, X.-Y. Liu, and J. Q. Wang, “Long-lasting up-regulation of orexin receptor type 2 protein levels in the rat nucleus accumbens after chronic cocaine administration,” Journal of Neurochemistry, vol. 103, no. 1, pp. 400–407, 2007.
- R. J. Smith, R. E. See, and G. Aston-Jones, “Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking,” European Journal of Neuroscience, vol. 30, no. 3, pp. 493–503, 2009.
- R. J. Smith, P. Tahsili-Fahadan, and G. Aston-Jones, “Orexin/hypocretin is necessary for context-driven cocaine-seeking,” Neuropharmacology, vol. 58, no. 1, pp. 179–184, 2010.
- J. A. Hollander, Q. Lu, M. D. Cameron, T. M. Kamenecka, and P. J. Kenny, “Insular hypocretin transmission regulates nicotine reward,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 49, pp. 19480–19485, 2008.
- A. Plaza-Zabala, E. Martín-García, L. De Lecea, R. Maldonado, and F. Berrendero, “Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior,” Journal of Neuroscience, vol. 30, no. 6, pp. 2300–2310, 2010.
- R. Sharf, M. Sarhan, and R. J. DiLeone, “Role of orexin/hypocretin in dependence and addiction,” Brain Research, vol. 1314, pp. 130–138, 2010.
- A. Bonci and S. Borgland, “Role of orexin/hypocretin and CRF in the formation of drug-dependent synaptic plasticity in the mesolimbic system,” Neuropharmacology, vol. 56, no. 1, pp. 107–111, 2009.
- J. K. Richards, J. A. Simms, P. Steensland et al., “Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats,” Psychopharmacology, vol. 199, no. 1, pp. 109–117, 2008.
- N. Cannella, D. Economidou, M. Kallupi et al., “Persistent increase of alcohol-seeking evoked by neuropeptide S: an effect mediated by the Hypothalamic Hypocretin System,” Neuropsychopharmacology, vol. 34, no. 9, pp. 2125–2134, 2009.
- B. Jupp, E. Krstew, G. Dezsi, and A. J. Lawrence, “Discrete cue-conditioned alcohol-seeking after protracted abstinence: pattern of neural activation and involvement of orexin1 receptors,” British Journal of Pharmacology, vol. 162, no. 4, pp. 880–889, 2011.
- J. R. Shoblock, N. Welty, L. Aluisio et al., “Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement,” Psychopharmacology, vol. 215, no. 1, pp. 191–203, 2011.
- D. Quarta, E. Valerio, D. M. Hutcheson, G. Hedou, and C. Heidbreder, “The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization,” Neurochemistry International, vol. 56, no. 1, pp. 11–15, 2010.
- U. Rudzińska and J. Zalewska-Kaszubska, “Role of endogenous neuropeptides in the pathomechanism of alcohol addiction,” Postpy Higieny i Medycyny Doświadczalnej, vol. 63, pp. 643–652, 2009.
- H. Azizi, J. Mirnajafi-Zadeh, K. Rohampour, and S. Semnanian, “Antagonism of orexin type 1 receptors in the locus coeruleus attenuates signs of naloxone-precipitated morphine withdrawal in rats,” Neuroscience Letters, vol. 482, no. 3, pp. 255–259, 2010.
- T. Mori, S. Ito, T. Kuwaki, M. Yanagisawa, T. Sakurai, and T. Sawaguchi, “Monoaminergic neuronal changes in orexin deficient mice,” Neuropharmacology, vol. 58, no. 4-5, pp. 826–832, 2010.
- M. H. James, J. L. Charnley, E. M. Levi et al., “Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical to regulating cue-induced reinstatement of cocaine-seeking,” International Journal of Neuropsychopharmacology, vol. 14, no. 5, pp. 684–690, 2011.
- S. L. Borgland, M. A. Ungless, and A. Bonci, “Convergent actions of orexin/hypocretin and CRF on dopamine neurons: emerging players in addiction,” Brain Research, vol. 1314, pp. 139–144, 2010.
- B. Boutrel, N. Cannella, and L. de Lecea, “The role of hypocretin in driving arousal and goal-oriented behaviors,” Brain Research, vol. 1314, pp. 103–111, 2010.
- I. V. Estabrooke, M. T. McCarthy, E. Ko et al., “Fos expression in orexin neurons varies with behavioral state,” Journal of Neuroscience, vol. 21, no. 5, pp. 1656–1662, 2001.
- U. Shalev, J. W. Grimm, and Y. Shaham, “Neurobiology of relapse to heroin and cocaine seeking: a review,” Pharmacological Reviews, vol. 54, no. 1, pp. 1–42, 2002.
- J. Han, Y. H. Li, Y. J. Bai, et al., “Role of hypothalamic orexin in drug addiction,” Sheng Li Ke Xue Jin Zhan, vol. 38, pp. 327–330, 2007.
- B. Wang, Z.-B. You, and R. A. Wise, “Reinstatement of cocaine seeking by hypocretin (Orexin) in the ventral tegmental area: independence from the Local Corticotropin-Releasing Factor Network,” Biological Psychiatry, vol. 65, no. 10, pp. 857–862, 2009.
- S. L. Borgland, S. A. Taha, F. Sarti, H. L. Fields, and A. Bonci, “Orexin a in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine,” Neuron, vol. 49, no. 4, pp. 589–601, 2006.
- M. Narita, Y. Nagumo, S. Hashimoto et al., “Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine,” Journal of Neuroscience, vol. 26, no. 2, pp. 398–405, 2006.
- Y. Zhou, J. Bendor, L. Hofmann, M. Randesi, A. Ho, and M. J. Kreek, “Mu opioid receptor and orexin/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal,” Journal of Endocrinology, vol. 191, no. 1, pp. 137–145, 2006.
- J. Strang, J. Bearn, M. Farrell et al., “Route of drug use and its implications for drug effect, risk of dependence and health consequences,” Drug and Alcohol Review, vol. 17, no. 2, pp. 197–211, 1998.
- G. C. Harris, M. Wimmer, J. F. Randall-Thompson, and G. Aston-Jones, “Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward,” Behavioural Brain Research, vol. 183, no. 1, pp. 43–51, 2007.
- C. von der Goltz, A. Koopmann, C. Dinter et al., “Orexin and leptin are associated with nicotine craving: a link between smoking, appetite and reward,” Psychoneuroendocrinology, vol. 35, no. 4, pp. 570–577, 2010.
- M. L. Rusch, R. Lozada, R. A. Pollini et al., “Polydrug use among IDUs in Tijuana, Mexico: correlates of methamphetamine use and route of administration by gender,” Journal of Urban Health, vol. 86, no. 5, pp. 760–775, 2009.